Skip to main navigation

About

Who We Are

Management Team
Board of Directors
Program Partners

Pipeline

Cardiovascular
Oncology
Respiratory
Ophthalmology
Inflammatory Disease

Patients

Investors

News & Events

News Releases
Events
Presentations

Stock

Stock Quote & Chart
Analyst Coverage

Governance

Documents & Charters
Management Team
Board of Directors
Committee Composition
Board Diversity Matrix

Financials

SEC Filings

IR Resources

Investor FAQs
Email Alerts
Contact IR

Contact

English
Chinese, Simplified

News Releases

Year

December 19, 2022

Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore

December 13, 2022

LianBio Announces President and Chief Strategy Officer Departure

November 10, 2022

LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 10, 2022

LianBio to Participate in Upcoming Investor and Industry Events

November 9, 2022

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

November 1, 2022

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

September 7, 2022

Nanobiotix and LianBio Announce First Patient Enrolled in Asia in Phase 3 Nanoray-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

August 11, 2022

LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022

LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

June 2, 2022

LianBio to Participate in June Investor Events

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

Print Page

Email Alerts

RSS Feeds

Contact IR

Connect with us on social media.

About

Who We Are Management Team Board of Directors Program Partners

Pipeline Cardiovascular Oncology Respiratory Ophthalmology Inflammatory Disease

Patients

Investors News & Events Stock Governance Financials IR Resources

Contact

© 2023 LianBio. All Rights Reserved.